Fischer Medical Ventures Ltd
Fischer Medical Ventures Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
2 of 4 strong
The short version
Fischer Medical Ventures targets a 15%-20% market share in the domestic and Asian MRI markets within 2-3 years, supported by a strong order book and favorable government policies. Fischer Medical Ventures expects to sustain growth aligned with the MedTech industry's macro growth rate of 15-20% CAGR, driven by government policies favoring Make-In-India and Atmanirbhar Bharat initiatives.
From Fischer Medical Ventures Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Fischer Medical Ventures targets a 15%-20% market share in the domestic and Asian MRI markets within 2-3 years, supported by a strong order book and favorable government policies.
- The total addressable market (TAM) for MRI devices in India is around 500 units per year, expected to grow over 1000 units annually in 3-4 years, driven by government health missions.
- Growth is expected to be broad-based across Radiology (MRI and CT) and Preventive Healthcare segments, with revenue contribution expected to be almost equally split between these two in 2-3 years.
- Company aims to leverage Make-In-India and Atmanirbhar Bharat initiatives along with import substitution to drive growth aligned with sector CAGR of 15%-20%.
2 more points from Fischer Medical Ventures Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Fischer Medical Ventures Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current manufacturing capacity: About 80 MRI machines per year in one shift; can be increased to 150-160 with two shifts.
- Facility expansion plans underway: Expansion of manufacturing facility to include other imaging lines such as CT scanners.
- Preventive healthcare capacity expansion: Focus on people (AI, software development) and server infrastructure rather than hardware manufacturing.
- Supply chain and regulatory focus: Continued efforts on obtaining international regulatory approvals for exports; current emphasis remains on domestic market.
2 more points from Fischer Medical Ventures Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fischer Medical Ventures Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Fischer Medical Ventures has a strong order book currently.
- Orders are being fulfilled as and when they arise, especially in the MRI segment.
- The sales cycle for MRI machines ranges from 6 to 9 months, sometimes up to 12 months.
- The company expects good order inflow for the rest of H2 FY '26 and into the next year.
2 more points from Fischer Medical Ventures Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Fischer Medical Ventures Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹101 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fischer Medical Ventures Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Tarsons Products Ltd (Q2 FY26)
Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities. Key concall takeaways…
- QMS Medical Allied Services Ltd (Q2 FY26)
The only related transaction noted is the recent acquisition of Saarathi increasing stake from 51% to 76%, but no fundraising details were shared with respect…
- Vasa Denticity Ltd (Q2 FY26)
Growth levers include increasing active customers (e.g., from 60,000 to 100,000 monthly) and increasing wallet share per customer (e.g., from 15% to 40%). Key…
Arthneeti Pro · Annual
Fischer Medical Ventures Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fischer Medical Ventures Ltd Q2 FY26 results?
Fischer Medical Ventures targets a 15%-20% market share in the domestic and Asian MRI markets within 2-3 years, supported by a strong order book and favorable government policies. Fischer Medical Ventures expects to sustain growth aligned with the MedTech industry's macro growth rate of 15-20% CAGR, driven by government policies favoring Make-In-India and Atmanirbhar Bharat initiatives.
What is Fischer Medical Ventures Ltd share price analysis?
Fischer Medical Ventures Ltd currently shows a below-average growth signal. The stock trades at a P/E of 104.7 with a market cap of ₹2,564 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fischer Medical Ventures Ltd planning capital expenditure?
Current manufacturing capacity: About 80 MRI machines per year in one shift; can be increased to 150-160 with two shifts.
Keep Fischer Medical Ventures Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.